NEW YORK (GenomeWeb News) – HistoRx said today that it has signed a three-year agreement to supply its biomarker analysis technology to drugmaker Eli Lilly and Company.
The company said it has extended and expanded a 2005 agreement to make its Aqua technology available to Lilly for use in its pharmaceutical development programs.
Under the agreement, HistoRx will give Lilly’s researchers access to the biomarker analysis technology and it will develop customized immunohistochemical assays for use in Lilly’s drug programs. HistoRx also gains the option to commercialize the assays and reagents that are developed over the course of the partnership for use as predictive diagnostics.
Financial terms of the agreement were not released.